Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.
Bill Williams says BriaCell's phase 3 seeks a 40% reduction in mortality. If it misses that, the company can continue and aim for a 30% reduction; FDA agreed either result would support full approval for the therapy, so no separate confirmatory study would be needed.
Bill Williams says BriaCell's engineered OTS cell lines express 15 HLA molecules across four lines. That lets them single-match over 99% of the population and double-match over 90%, making a personalized off-the-shelf therapy practical after only a one-week saliva test rather than complex tumor sequencing.
Bill Williams describes a patient who had failed 13 prior therapy attempts and then had universal tumor regression on Bria-IMT plus a checkpoint inhibitor. Another with brain metastasis stayed on therapy for two years, challenging the idea that cancer vaccines only work in healthier, earlier-stage patients.
Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.
Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.
